Glutamate-gated chloride channel · SINGLE PROTEIN · Onchocerca volvulus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Glutamate-gated chloride channel shows approved-linked disease relevance led by Helminthiasis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q25634. Start with Helminthiasis, then reuse UniProt Q25634 as the stable protein anchor across project notes and exports.
Start with Helminthiasis, then reuse UniProt Q25634 as the stable protein anchor across project notes and exports.
Glutamate-gated chloride channel shows approved-linked disease relevance led by Helminthiasis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Helminthiasis because it currently carries approved-linked support. Linked drugs include IVERMECTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGlutamate-gated chloride channel
Review this target as Glutamate-gated chloride channel, mapped to UniProt Q25634. Sequence length is 351 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutamate-gated chloride channel as ChEMBL target CHEMBL2363051, mapped to UniProt Q25634. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Glutamate-gated chloride channel is the right protein anchor across sources, using UniProt Q25634 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Helminthiasis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Glutamate-gated chloride channel |
| Target Type | SINGLE PROTEIN |
| Organism | Onchocerca volvulus |
| UniProt | Q25634 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Glutamate-gated chloride channel |
| UniProt Accession | Q25634 |
| Component Type | Protein |
| Sequence Length | 351 aa |
Glutamate-gated chloride channel
Review this target as Glutamate-gated chloride channel, mapped to UniProt Q25634. Sequence length is 351 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Glutamate-gated chloride channel shows approved-linked disease relevance led by Helminthiasis. 5 more disease programs remain visible in the same review block.
Start review with Helminthiasis because it currently carries approved-linked support. Linked drugs include IVERMECTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.